CHIP: a clonal odyssey of the bone marrow niche
WE Schleicher, B Hoag, M De Dominici… - The Journal of Clinical …, 2024 - jci.org
Clonal hematopoiesis of indeterminate potential (CHIP) is characterized by the selective
expansion of hematopoietic stem and progenitor cells (HSPCs) carrying somatic mutations …
expansion of hematopoietic stem and progenitor cells (HSPCs) carrying somatic mutations …
Impact of p53-associated acute myeloid leukemia hallmarks on metabolism and the immune environment
M Chomczyk, L Gazzola, S Dash, P Firmanty… - Frontiers in …, 2024 - frontiersin.org
Acute myeloid leukemia (AML), an aggressive malignancy of hematopoietic stem cells, is
characterized by the blockade of cell differentiation, uncontrolled proliferation, and cell …
characterized by the blockade of cell differentiation, uncontrolled proliferation, and cell …
The dynamic evolution of lineage switch under CD19 CAR-T treatment in non-KMT2A rearranged B-ALL patients
S Qiu, Y Mei, R Gu, Y Liu, M Chen, H Xing, K Tang… - Leukemia, 2024 - nature.com
Over the last decade, chimeric antigen receptor (CAR)-T, especially the CD19-directed CAR-
T therapy has achieved major success in B-cell malignancies. Despite that, a considerable …
T therapy has achieved major success in B-cell malignancies. Despite that, a considerable …
Acute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety meta-analysis of randomized controlled trials combined with a …
PM Morice, S Khalife-Hachem, M Sassier… - Blood Cancer …, 2024 - nature.com
Dear Editor, Since the first Food and Drug Administration (FDA) approval of lenalidomide in
treating patients with myelodysplastic syndromes (MDS) in 2005, its indications have been …
treating patients with myelodysplastic syndromes (MDS) in 2005, its indications have been …
Diagnosis of acute lymphoblastic leukaemia: an overview of the current genomic classification, diagnostic approaches, and future directions
W Walter, I Iacobucci, M Meggendorfer - Histopathology, 2024 - Wiley Online Library
B‐acute lymphoblastic leukaemia (B‐ALL) is a haematological disease resulting from
haematopoietic system dysfunction, leading to the unchecked growth of immature B …
haematopoietic system dysfunction, leading to the unchecked growth of immature B …
“Myeloid” Mutations in ALL Are Not Uncommon: Implications for Etiology and Therapies
I Iacobucci - Blood Cancer Discovery, 2024 - AACR
In Blood Cancer Discovery, Saygin and colleagues report that somatic variants that are
recurrent in myeloid malignancies can also occur with high frequency (16%) in adult acute …
recurrent in myeloid malignancies can also occur with high frequency (16%) in adult acute …
How I Treat Older Patients with Ph/BCR-ABL Negative Acute Lymphoblastic Leukaemia
N Gökbuget, B Steffen - Blood, 2024 - Elsevier
Despite advancements in new treatments, management of older patients with acute
lymphoblastic leukaemia (ALL) remains an unmet medical need. With increasing age, ALL …
lymphoblastic leukaemia (ALL) remains an unmet medical need. With increasing age, ALL …